Q122 started slow but ended on a bright note as COVID-19 concerns faded and surgical volumes approached pre-pandemic levels.

Virtually all orthopedic/spine companies experienced the same pattern with elective procedures during the quarter. In general, elective procedure case counts were pressured in January through the beginning of February as a surge in COVID-19 cases impacted patients and contributed to staffing shortages at healthcare facilities. However, by the end of the quarter elective procedures approached or returned to pre-COVID levels.

Among the many topics covered in detail in our comprehensive Q122 OrthoBio Market Recap* are:

Wallaby Medical CEO and founder Michael Alper discusses the Company’s recent acquisition of phenox GmBH and positioning the Company for success in an interview with SmartTRAK

With no overlap from a product or geographic perspective, Wallaby Medical’s recent acquisition of phenox GmBH was a “match made in heaven” according to Wallaby’s CEO and founder Michael Alper. In an interview with SmartTRAK, Alper discusses the acquisition, company synergies, complementary channels and the Company’s strategies for global expansion and becoming a leader in the market for neurovascular intervention.

To find out more, including details about the acquisition, the Company and its key products and markets, click on the following video to listen to the interview recorded via Zoom (21:07 min). A link to download the complete transcript of the interview is also provided below.

For Q122, US Joint Fluid Replacement market players continued on a running growth, which did not seem too disrupted by the COVID Omicron variant. Furthermore, some players shared that despite physicians’ offices not yet running at 100% levels, company sales representatives were able to hold face-to-face visits and secure new orders.

Rafael Carbunaru, PhD, Boston Scientific’s VP of R&D, discusses DBS therapy and STIMVIEW XT, the Company’s new advanced visualization software for DBS programming, in an in-depth interview with SmartTRAK at INS 2022

Rafael Carbunaru, PhD, vice president of research and development for Boston Scientific (BSX), discusses deep brain stimulation (DBS) and STIMVIEW XT, the Company’s new advanced visualization software for DBS programming in an in-depth interview with SmartTRAK at the International Neuromodulation Society (INS) World Congress in Barcelona, Spain held May 21-26.

Used with the Vercise Genus DBS portfolio and developed in collaboration with Brainlab, STIMVIEW XT uses patient-specific 3D visualization of patient anatomy and enables clinicians to see, shape and steer DBS therapy using point-and-click interface designed to simplify programming, save time and better personalize therapy.

To find out more about STIMVIEW XT, DBS workflows and BSX’s vision for DBS, click on the following video to listen to the interview recorded live at INS 2022 (45:16 min). For more details, interview topics by timecode are provided below. A link to download a complete transcript of the interview is also available below.

SmartTRAK reports that challenging conditions lead to minimal innovation in Paris.

It was third time lucky for the approximately 3,500 attendees of the 2022 European Wound Management Association (EWMA) conference in Paris. Although not yet back to a pre-pandemic number of participants, it was encouraging to see an international presence without the barrier of COVID-19 restrictions. Previous dates in 2020 and early 2022 fell to the pandemic, so great credit goes to the organizers and exhibitors for persevering and delivering a positive and engaging event.

Among the many topics covered in this SmartTRAK perspective article, which you can download here, are:

• MDR Consuming R&D Resources
• Clouds over Germany - Is There a Silver Lining?
• Establishing a European Foothold
• The Trend in Using Fewer Layers in Compress

Among the many topics covered in detail in our comprehensive Q122 Spinal Cord Stimulation Market Recap* are:

The return of elective procedure volumes, new product offerings and a busy first quarter of acquisitions all supported healthy growth for the Extremities Market

While growth drivers varied for specific companies in Q122, the return of elective procedure volumes helped drive double-digit growth for several market players. Stryker*, the Extremities Market leader, benefited from the return of elective procedures in the US. Its US Foot & Ankle and Upper Extremities business segments contributed to the Company’s US Trauma & Extremities growth during the quarter. Stryker also noted during its earnings call that ...

Among the many topics covered in detail in our comprehensive Q122 Extremities Market Recap* are:

Ryan Lakin, Abbott DVP of R&D, discusses opportunities in neuromodulation in an interview with SmartTRAK at INS 2022